首页> 外文期刊>Asian spine journal. >Outcomes of Fluoroscopically Guided Lumbar Transforaminal Epidural Steroid Injections in Degenerative Lumbar Spondylolisthesis Patients
【24h】

Outcomes of Fluoroscopically Guided Lumbar Transforaminal Epidural Steroid Injections in Degenerative Lumbar Spondylolisthesis Patients

机译:退行性腰椎滑脱患者的荧光镜引导下腰椎椎间孔穿刺硬膜外类固醇注射的结果

获取原文
获取外文期刊封面目录资料

摘要

Study Design A prospective cohort. Purpose To report the short and long term outcomes of fluoroscopically guided lumbar transforaminal epidural steroid injection (TFESI) in degenerative lumbar spondylolisthesis (DLS) patients. Overview of Literature TFESI has been widely used for the treatment of lumbosacral radicular pains. However, to our knowledge, there has been no study which has evaluated the outcomes of TFESI in patients with DLS. Methods The DLS patients received fluoroscopically guided lumbar TFESI with 80 mg of methylprednisolone and 2 mL of 1% lidocaine hydrochloride. Patients were evaluated by an independent observer before the initial injection, at 2 weeks, at 6 weeks, at 3 months, and at 12 months after the injections. Visual analog scale (VAS), Roland 5-point pain scale, standing tolerance, walking tolerance, and patient satisfaction scale were evaluated for outcomes. Results Thirty three DLS patients treated with TFESI, who were completely followed up, were included in this study. The average number of injections per patient was 1.9 (range from 1 to 3 injections per patient). Significant improvements in VAS and Roland 5-point pain scale were observed over the follow up period from 2 weeks to 12 months. However, the standing and walking tolerance were not significantly improved after 2 weeks. At 2 weeks, the patient satisfaction scale was highest, although, these outcomes declined with time. The DLS patients with one level of spinal stenosis showed significantly better outcome than the DLS patients with two levels of spinal stenosis. Five patients (13%) underwent surgical treatment during the 3 to 12 months follow up. Conclusions TFESI provides short term improvements in VAS and Roland 5-point pain scale, standing tolerance, walking tolerance and patient satisfaction scale in DLS patients. In the long term, it improves VAS but limits the improvements in Roland 5-point pain scale, standing tolerance, walking tolerance and patient satisfaction scale.
机译:研究设计前瞻性队列。目的报告在退行性腰椎滑脱症(DLS)患者中,经荧光镜引导的经椎间孔椎间孔硬膜外类固醇注射(TFESI)的短期和长期结果。文献综述TFESI已被广泛用于腰部神经根痛的治疗。然而,据我们所知,尚无研究评估DLS患者TFESI的预后。方法DLS患者接受X线透视引导下腰椎TFESI,其中含80 mg甲基强的松龙和2 mL 1%盐酸利多卡因。在初次注射前,注射后2周,6周,3个月和12个月时,由独立的观察者对患者进行评估。评估视觉模拟量表(VAS),罗兰5点疼痛量表,站立耐受性,步行耐受性和患者满意度量表。结果本研究纳入了33例接受TFESI治疗的DLS患者,并对其进行了完全随访。每位患者的平均注射次数为1.9(每位患者1至3次注射)。在2周至12个月的随访期内,观察到了VAS和Roland 5点疼痛量表的显着改善。但是,站立和行走耐受性在2周后没有明显改善。在2周时,患者满意度最高,尽管这些结果随时间而下降。具有两个水平的椎管狭窄的DLS患者显示出比具有两个水平的椎管狭窄的DLS患者明显更好的结局。在3到12个月的随访期间,有5名患者(13%)接受了手术治疗。结论TFESI可在DLS患者中短期改善VAS和Roland 5点疼痛量表,站立耐受性,步行耐受性和患者满意度量表。从长远来看,它可以改善VAS,但会限制Roland 5点疼痛量表,站立耐力,行走耐力和患者满意度的改善。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号